Sherbrooke Medical Limited 14785297 false 2024-05-01 2025-04-30 2025-04-30 The principal activity of the company is general medical practice activities. Digita Accounts Production Advanced 6.30.9574.0 true true 14785297 2024-05-01 2025-04-30 14785297 2025-04-30 14785297 core:RetainedEarningsAccumulatedLosses 2025-04-30 14785297 core:ShareCapital 2025-04-30 14785297 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 14785297 core:FurnitureFittingsToolsEquipment 2025-04-30 14785297 bus:SmallEntities 2024-05-01 2025-04-30 14785297 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 14785297 bus:FullAccounts 2024-05-01 2025-04-30 14785297 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 14785297 bus:RegisteredOffice 2024-05-01 2025-04-30 14785297 bus:Director1 2024-05-01 2025-04-30 14785297 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 14785297 core:ComputerEquipment 2024-05-01 2025-04-30 14785297 core:FurnitureFittingsToolsEquipment 2024-05-01 2025-04-30 14785297 countries:AllCountries 2024-05-01 2025-04-30 14785297 2024-04-30 14785297 core:FurnitureFittingsToolsEquipment 2024-04-30 14785297 2023-04-06 2024-04-30 14785297 2024-04-30 14785297 core:RetainedEarningsAccumulatedLosses 2024-04-30 14785297 core:ShareCapital 2024-04-30 14785297 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 14785297 core:FurnitureFittingsToolsEquipment 2024-04-30 iso4217:GBP xbrli:pure

Registration number: 14785297

Sherbrooke Medical Limited
Annual Report and Unaudited Filleted Abridged Financial Statements
for the Year Ended 30 April 2025

Sherbrooke Medical Limited

Contents

Abridged Balance Sheet | 1
Notes to the Unaudited Abridged Financial Statements | 2 to 3

Sherbrooke Medical Limited

(Registration number: 14785297)
Abridged Balance Sheet as at 30 April 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 4 | 2,010 | 3,015
Current assets |  |  |
Debtors |  | 30 | 5
Cash at bank and in hand |  | 10,357 | 7,113
|  | 10,387 | 7,118
Creditors: Amounts falling due within one year |  | (10,624) | (6,476)
Net current (liabilities)/assets |  | (237) | 642
Net assets |  | 1,773 | 3,657
Capital and reserves |  |  |
Called up share capital |  | 100 | 100
Profit and loss account |  | 1,673 | 3,557
Total equity |  | 1,773 | 3,657

For the financial year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

| The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
| The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the director on 7 January 2026

Dr L Heathorn

Director

Sherbrooke Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 April 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales .

The address of its registered office is:
Calyx House
South Road
Taunton
Somerset
TA1 3DU

These financial statements were authorised for issue by the director on 7 January 2026.

2 | Accounting policies

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Sherbrooke Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 April 2025

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Office Equipment | 25% Straight line

3 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

4 | Tangible assets

| Office equipment £ | Total £
Cost or valuation
At 1 May 2024 | 4,020 | 4,020
At 30 April 2025 | 4,020 | 4,020
Depreciation
At 1 May 2024 | 1,005 | 1,005
Charge for the year | 1,005 | 1,005
At 30 April 2025 | 2,010 | 2,010
Carrying amount
At 30 April 2025 | 2,010 | 2,010
At 30 April 2024 | 3,015 | 3,015

5 | Related party transactions

Transactions with directors During the year, Dr L Heathorn went overdrawn on their director's loan account. The maximum overdrawn balance during the year was £25. At the year end the amount outstanding was £25.